GlioblastomaGlioConnectNCT07628257
Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up
A study testing 18F-FDG PET/MRI with additional DTI and rs-fMRI sequences in people with Glioblastoma, run by Centre Paul Strauss at 1 site in France.
Trial summary
The aim of this study is to determine whether the diffuse cerebral metabolic disturbances observed in glioblastoma are exclusively linked to the direct and indirect effects of tumor infiltration (particularly structural disconnection), or whether they also reflect a more global alteration of neurometabolic and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glioblastoma
- What is being tested?
- 18F-FDG PET/MRI with additional DTI and rs-fMRI sequences
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteFrance
- Study dates
- 15 Sep 2026to 15 Sep 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients
- Patients with glioblastoma
- Patients treated in the Nuclear Medicine \& Molecular Imaging Department of the Strauss Institute for PET/MRI scans for:
- Preoperative metabolic evaluation of a brain-expanding lesion
Who cannot join
- Contraindications to MRI
- Minor or incapacitated adult
- Patient deprived of liberty
- Patient under legal guardianship
- Patient unable to consent
- Pregnant or breastfeeding woman
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Institut public de cancérologie Strauss Europe
Strasbourg, 67033
Claire VIT, (0)388258529 ext. +33, promotion-rc@institut-strauss.fr
Manon VOEGELIN, (0)368339523 ext. +33, promotion-rc@institut-strauss.fr
About this study
Official title: Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of Diffusion Tensor Imaging (DTI) and Resting State Functional MRI (Rs-fMRI) to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up
The aim of this study is to determine whether the diffuse cerebral metabolic disturbances observed in glioblastoma are exclusively linked to the direct and indirect effects of tumor infiltration (particularly structural disconnection), or whether they also reflect a more global alteration of neurometabolic and neurovascular coupling mechanisms.
This approach thus aims to better understand the pathophysiological basis of cognitive impairment in glioblastoma and to characterize the impact of the disease at the level of brain networks.
- Conditions
- Glioblastoma
- Being tested
- 18F-FDG PET/MRI with additional DTI and rs-fMRI sequences
- Medical subject headings
- Glioblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
18F-FDG PET/MRI with additional DTI and rs-fMRI sequencesOther
fluorodeoxyglucose (Fluor18) (18F-FDG) PET/MRI with additional DTI and rs-fMRI sequences correlation with neuropsychological tests
| Study group | Role | What they receive |
|---|---|---|
| Patients with glioblastoma treated in the Department of Nuclear Medicine & Molecular Imaging | Other | Not described Receives: Other: 18F-FDG PET/MRI with additional DTI and rs-fMRI sequences |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between cortical energy activity (FDG PET), axonal morphological connectivity (DTI - MRI), synchronous neuronal activity (rs-fMRI), and preoperative neuropsychological performance before surgery
Measured: Before surgery
Secondary outcomes (1)
correlation between cortical energy activity (FDG PET), axonal morphological connectivity (DTI - MRI), synchronous neuronal activity (rs-fMRI), and preoperative neuropsychological performance after surgery
Measured: After surgery, through the study, i.e. for a maximum of 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2026
- Study start15 Sep 2026 (estimated)
- Primary completion15 Sep 2030 (estimated)
- Study completion15 Sep 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlioblastomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Paul Strauss
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Izzie-Jacques NAMER, MD, PhD, Principal investigator, Institut Public De Cancerologie Strauss Europe
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07628257
- Sponsor's protocol ID
- 2026-005
- Other IDs
- 2026-A01255-46
- Acronym
- GlioConnect
- Status last verified
- Jun 2026
- First submitted
- 28 May 2026
- Last updated
- 4 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of Diffusion Tensor Imaging (DTI) and Resting State Functional MRI (Rs-fMRI) to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up
- ClinicalTrials.gov ID
- NCT07628257
- Acronym / sponsor ID
- GlioConnect / 2026-005
- Conditions
- Glioblastoma
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Centre Paul StraussUniversity, hospital or other
- Study start
- 15 Sep 2026 (estimated)
- Primary completion
- 15 Sep 2030 (estimated)
- Study completion
- 15 Sep 2030 (estimated)
- First posted
- 4 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to determine whether the diffuse cerebral metabolic disturbances observed in glioblastoma are exclusively linked to the direct and indirect effects of tumor infiltration (particularly structural disconnection), or whether they also reflect a more global alteration of neurometabolic and neurovascular coupling mechanisms.
This approach thus aims to better understand the pathophysiological basis of cognitive impairment in glioblastoma and to characterize the impact of the disease at the level of brain networks.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with glioblastoma treated in the Department of Nuclear Medicine & Molecular Imaging | Other | Other: 18F-FDG PET/MRI with additional DTI and rs-fMRI sequences |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adult patients
- Patients with glioblastoma
- Patients treated in the Nuclear Medicine \& Molecular Imaging Department of the Strauss Institute for PET/MRI scans for:
Key exclusion criteria (6 listed)
- Contraindications to MRI
- Minor or incapacitated adult
- Patient deprived of liberty
- Patient under legal guardianship
- Patient unable to consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 18F-FDG PET/MRI with additional DTI and rs-fMRI sequencesfluorodeoxyglucose (Fluor18) (18F-FDG) PET/MRI with additional DTI and rs-fMRI sequences correlation with neuropsychological tests | Other | Patients with glioblastoma treated in the Department of Nuclear Medicine & Molecular Imaging |
Primary outcome
Correlation between cortical energy activity (FDG PET), axonal morphological connectivity (DTI - MRI), synchronous neuronal activity (rs-fMRI), and preoperative neuropsychological performance before surgery
Time frame: Before surgery
1 secondary outcome
correlation between cortical energy activity (FDG PET), axonal morphological connectivity (DTI - MRI), synchronous neuronal activity (rs-fMRI), and preoperative neuropsychological performance after surgery
Time frame: After surgery, through the study, i.e. for a maximum of 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2026.
Related trials for Glioblastoma
Active, not recruitingPhase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Active, not recruitingPhase 1
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Glioblastoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Izzie-Jacques NAMER, MD, PhD principal investigator
Institut Public De Cancerologie Strauss Europe
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 18F-FDG PET/MRI with additional DTI and rs-fMRI sequences in people with Glioblastoma, run by Centre Paul Strauss at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Claire VIT ((0)388258529 ext. +33, promotion-rc@institut-strauss.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between cortical energy activity (FDG PET), axonal morphological connectivity (DTI - MRI), synchronous neuronal activity (rs-fMRI), and preoperative neuropsychological performance before surgery (time frame: Before surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.